Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment_老虎社区_美港股上老虎

Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment

seekingalpha2021-09-03

Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results. Shares slide nearly 82% post market. In ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

172

Zified
·2021-09-05
Ok
回复
2
举报
Short
·2021-09-03
What is more in product development pipeline? Good moment to buy or stay away?
回复
3
举报
JoelLee
·2021-09-03
Reply and comment pls thx
回复
2
举报
Eric2166
·2021-09-03
sad 😭
回复
3
举报
收起
- SafetyFirst:
  commen
  2021-09-03
  回复
  举报
gupzbajaj
·2021-09-03
Is it worth buying?Can this stock make a comeback like Luckin coffee ?
回复
3
举报
Tamashii
·2021-09-03
Jialat la!
回复
3
举报
收起
- Tamashii:
  compare with DIDI and Virgin Galactic this still ok!
  2021-09-03
  回复
  举报
ken26ksh
·2021-09-03
😔😔😔
回复
1
举报
Begreen
·2021-09-03
[Sweats] [Sweats]
回复
1
举报
ToongMH
·2021-09-03
Oh my god!
回复
2
举报
pointe
·2021-09-03
Ouch…
回复
2
举报
tan0524u
·2021-09-03
Likes for all
回复
4
举报
收起
- SafetyFirst:
  comment
  2021-09-19
  回复
  举报
Ameliakoh
·2021-09-03
Stay clam
回复
7
举报
收起
- ToongMH:
  noted
  2021-09-03
  回复
  举报
- pointe:
  Yup
  2021-09-03
  回复
  举报
Dragon1976
·2021-09-03
Roar
回复
6
举报
Huatster
·2021-09-03
Wow
回复
5
举报
ballista1
·2021-09-03
Omg
回复
5
举报
brightsun
·2021-09-03
My 韭菜
回复
6
举报
收起
- Ameliakoh:
  🍀🍀
  2021-09-03
  回复
  举报
987ce65
·2021-09-03
Oh no
回复
4
举报
sickeninglim
·2021-09-03
Wow....
回复
10
举报
1c7647b7
·2021-09-03
Bdhsjbsvshh
回复
6
举报
Rara08
·2021-09-03
Wow
回复
4
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1186835624?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-09-03 07:39","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"1186835624","market":"us","top_or_hot":-1,"title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","media":"seekingalpha","content":"<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBRX","symbol_name":"Forte BioSciences Inc","start_time":0,"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","article_id":"1186835624","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","pubTimestamp":1630625981,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"translate_title":"FB-401处理剂报废后，Forte Biosciences股价下跌82%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBRX":0.9},"content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":814877557,"gmtCreate":1630809302079,"gmtModify":1631890256740,"author":{"id":"3575931476822699","authorId":"3575931476822699","authorIdStr":"3575931476822699","name":"Zified","avatar":"https://static.tigerbbs.com/2504476ab9db7b38867d7694e9c634e7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575931476822699"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/814877557","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815816020,"gmtCreate":1630665021160,"gmtModify":1631890218493,"author":{"id":"4091790236379980","authorId":"4091790236379980","authorIdStr":"4091790236379980","name":"Short","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4091790236379980"},"htmlText":"What is more in product development pipeline? Good moment to buy or stay away?","listText":"What is more in product development pipeline? Good moment to buy or stay away?","text":"What is more in product development pipeline? Good moment to buy or stay away?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815816020","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815382563,"gmtCreate":1630644500352,"gmtModify":1632468621571,"author":{"id":"3579882572140125","authorId":"3579882572140125","authorIdStr":"3579882572140125","name":"JoelLee","avatar":"https://static.tigerbbs.com/e1f6c92b13d94cba61906c07dbbb2ab6","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579882572140125"},"htmlText":"Reply and comment pls thx","listText":"Reply and comment pls thx","text":"Reply and comment pls thx","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815382563","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815941325,"gmtCreate":1630638481767,"gmtModify":1631891418222,"author":{"id":"3582865512656085","authorId":"3582865512656085","authorIdStr":"3582865512656085","name":"Eric2166","avatar":"https://static.tigerbbs.com/951d62faf57e5fbf7374b225853c8d0d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582865512656085"},"htmlText":"sad 😭","listText":"sad 😭","text":"sad 😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815941325","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5738924,"gmtCreate":1630642543098,"gmtModify":1631891418224,"authorId":3570965583958757,"author":{"id":3570965583958757,"authorId":3570965583958757,"name":"SafetyFirst","avatar":"https://static.tigerbbs.com/a6356c1a4c82b1755621f3b2631a6784","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815941325,"type":1,"supId":0,"prevId":0,"content":"commen","text":"commen","html":"commen"}],"langContent":"EN"},{"id":815940305,"gmtCreate":1630638288607,"gmtModify":1631888995679,"author":{"id":"3582203097187155","authorId":"3582203097187155","authorIdStr":"3582203097187155","name":"gupzbajaj","avatar":"https://static.tigerbbs.com/b0441cdcbc87c9f271dee51139b52dff","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582203097187155"},"htmlText":"Is it worth buying?Can this stock make a comeback like Luckin coffee ?","listText":"Is it worth buying?Can this stock make a comeback like Luckin coffee ?","text":"Is it worth buying?Can this stock make a comeback like Luckin coffee ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815940305","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815958908,"gmtCreate":1630637846104,"gmtModify":1631889315005,"author":{"id":"4087109479010510","authorId":"4087109479010510","authorIdStr":"4087109479010510","name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087109479010510"},"htmlText":"Jialat la!","listText":"Jialat la!","text":"Jialat la!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815958908","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5738221,"gmtCreate":1630637922272,"gmtModify":1631889314998,"authorId":4087109479010510,"author":{"id":4087109479010510,"authorId":4087109479010510,"name":"Tamashii","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815958908,"type":1,"supId":0,"prevId":0,"content":"compare with DIDI and Virgin Galactic this still ok!","text":"compare with DIDI and Virgin Galactic this still ok!","html":"compare with DIDI and Virgin Galactic this still ok!"}],"langContent":"EN"},{"id":815969277,"gmtCreate":1630636133699,"gmtModify":1631891744518,"author":{"id":"3586247634551228","authorId":"3586247634551228","authorIdStr":"3586247634551228","name":"ken26ksh","avatar":"https://static.tigerbbs.com/64235ed64966a3645379f94c283bdef9","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3586247634551228"},"htmlText":"😔😔😔","listText":"😔😔😔","text":"😔😔😔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815969277","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815989146,"gmtCreate":1630635320585,"gmtModify":1632469089903,"author":{"id":"3586230033668947","authorId":"3586230033668947","authorIdStr":"3586230033668947","name":"Begreen","avatar":"https://static.tigerbbs.com/ea08d58edd58086405f2b617c28993c8","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3586230033668947"},"htmlText":"[Sweats]&nbsp;[Sweats]&nbsp;","listText":"[Sweats]&nbsp;[Sweats]&nbsp;","text":"[Sweats] [Sweats]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815989146","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815938176,"gmtCreate":1630634411695,"gmtModify":1632469159005,"author":{"id":"3579230468032082","authorId":"3579230468032082","authorIdStr":"3579230468032082","name":"ToongMH","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579230468032082"},"htmlText":"Oh my god!&nbsp;","listText":"Oh my god!&nbsp;","text":"Oh my god!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815938176","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815992917,"gmtCreate":1630634050939,"gmtModify":1631893067453,"author":{"id":"4093612570926840","authorId":"4093612570926840","authorIdStr":"4093612570926840","name":"pointe","avatar":"https://static.tigerbbs.com/2228225cd04d557ec97467028247a938","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4093612570926840"},"htmlText":"Ouch…","listText":"Ouch…","text":"Ouch…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815992917","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815041221,"gmtCreate":1630632242163,"gmtModify":1631893392316,"author":{"id":"3567505470517950","authorId":"3567505470517950","authorIdStr":"3567505470517950","name":"tan0524u","avatar":"https://static.tigerbbs.com/36ccaf6467346df7588feaddbaa96926","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3567505470517950"},"htmlText":"Likes for all","listText":"Likes for all","text":"Likes for all","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815041221","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5923106,"gmtCreate":1632048428148,"gmtModify":1634792282359,"authorId":3570965583958757,"author":{"id":3570965583958757,"authorId":3570965583958757,"name":"SafetyFirst","avatar":"https://static.tigerbbs.com/a6356c1a4c82b1755621f3b2631a6784","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815041221,"type":1,"supId":0,"prevId":0,"content":"comment","text":"comment","html":"comment"}],"langContent":"EN"},{"id":815086411,"gmtCreate":1630630359633,"gmtModify":1631890072303,"author":{"id":"3574754838536636","authorId":"3574754838536636","authorIdStr":"3574754838536636","name":"Ameliakoh","avatar":"https://static.tigerbbs.com/4a747ab791603fb0a649736b10ec7454","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574754838536636"},"htmlText":"Stay clam&nbsp;","listText":"Stay clam&nbsp;","text":"Stay clam","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/815086411","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5737537,"gmtCreate":1630634422484,"gmtModify":1631890072315,"authorId":3579230468032082,"author":{"id":3579230468032082,"authorId":3579230468032082,"name":"ToongMH","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815086411,"type":1,"supId":5737522,"prevId":0,"content":"<u>noted</u>","text":"<u>noted</u>","html":"<u>noted</u>"},{"id":5737522,"gmtCreate":1630634339042,"gmtModify":1631890072304,"authorId":4093612570926840,"author":{"id":4093612570926840,"authorId":4093612570926840,"name":"pointe","avatar":"https://static.tigerbbs.com/2228225cd04d557ec97467028247a938","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815086411,"type":1,"supId":0,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"}],"langContent":"EN"},{"id":815014697,"gmtCreate":1630629936819,"gmtModify":1631890965723,"author":{"id":"3581667755269715","authorId":"3581667755269715","authorIdStr":"3581667755269715","name":"Dragon1976","avatar":"https://static.tigerbbs.com/490476b6972495f8a3fcdcab33e93aa0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581667755269715"},"htmlText":"Roar&nbsp;","listText":"Roar&nbsp;","text":"Roar","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815014697","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815038206,"gmtCreate":1630629077905,"gmtModify":1631886925337,"author":{"id":"3553940862995950","authorId":"3553940862995950","authorIdStr":"3553940862995950","name":"Huatster","avatar":"https://static.tigerbbs.com/d9dc702866f5062cdf4876ec185d9e88","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3553940862995950"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815038206","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815030534,"gmtCreate":1630628860528,"gmtModify":1631890407307,"author":{"id":"4091674598333310","authorId":"4091674598333310","authorIdStr":"4091674598333310","name":"ballista1","avatar":"https://static.tigerbbs.com/0eaa07c7e4d745cfdbbd207bd852aeb6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091674598333310"},"htmlText":"Omg","listText":"Omg","text":"Omg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815030534","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":815094497,"gmtCreate":1630628806919,"gmtModify":1631884894260,"author":{"id":"3570689780555896","authorId":"3570689780555896","authorIdStr":"3570689780555896","name":"brightsun","avatar":"https://static.tigerbbs.com/50f01966a534f410b4455882da98d0f9","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3570689780555896"},"htmlText":"My 韭菜","listText":"My 韭菜","text":"My 韭菜","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815094497","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5736448,"gmtCreate":1630630278598,"gmtModify":1631884894262,"authorId":3574754838536636,"author":{"id":3574754838536636,"authorId":3574754838536636,"name":"Ameliakoh","avatar":"https://static.tigerbbs.com/4a747ab791603fb0a649736b10ec7454","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":815094497,"type":1,"supId":0,"prevId":0,"content":"🍀🍀","text":"🍀🍀","html":"🍀🍀"}],"langContent":"CN"},{"id":815095241,"gmtCreate":1630628753283,"gmtModify":1632469693217,"author":{"id":"3582709856792743","authorId":"3582709856792743","authorIdStr":"3582709856792743","name":"987ce65","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582709856792743"},"htmlText":"Oh no","listText":"Oh no","text":"Oh no","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/815095241","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812777548,"gmtCreate":1630627885684,"gmtModify":1631893284024,"author":{"id":"3575453671192179","authorId":"3575453671192179","authorIdStr":"3575453671192179","name":"sickeninglim","avatar":"https://static.tigerbbs.com/0753a2906468fc16c39e5f831b2200d7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575453671192179"},"htmlText":"Wow....","listText":"Wow....","text":"Wow....","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812777548","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812777398,"gmtCreate":1630627869614,"gmtModify":1632469822273,"author":{"id":"3570486685609384","authorId":"3570486685609384","authorIdStr":"3570486685609384","name":"1c7647b7","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3570486685609384"},"htmlText":"Bdhsjbsvshh","listText":"Bdhsjbsvshh","text":"Bdhsjbsvshh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812777398","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":812778917,"gmtCreate":1630627595739,"gmtModify":1632469849293,"author":{"id":"3579125484417577","authorId":"3579125484417577","authorIdStr":"3579125484417577","name":"Rara08","avatar":"https://static.tigerbbs.com/ee915a47f3c554f599dce721c2397b4d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3579125484417577"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/812778917","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":172,"commentSize":33,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}